Peptides targeting toll-like receptor signalling pathways for novel immune therapeutics

Current Pharmaceutical Design

Volumn 16, Issue 9, 2010, Pages 1063-1080

  Gomariz, Rosa P ^a   Gutiérrez Cañas, Irene ^a   Arranz, Alicia ^a   Carrión, Mar ^a   Juarranz, Yasmina ^a   Leceta, Javier ^a   Martínez, Carmen ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Autoimmunity; Drug design; Immunotherapy; Inflammation; Neuropeptides; TLR; VIP

Indexed keywords

HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 70; HIGH MOBILITY GROUP B1 PROTEIN; HORMONE DERIVATIVE; HYALURONIC ACID; IMIQUIMOD; IMMUNOLOGICAL ADJUVANT; IMMUNOMODULATING AGENT; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; PEPTIDE DERIVATIVE; SUPPRESSOR OF CYTOKINE SIGNALING 1; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TOLL LIKE RECEPTOR AGONIST; TOLL LIKE RECEPTOR ANTAGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ADAPTIVE IMMUNITY; AGING; ALLERGIC DISEASE; ALLERGY; ASTHMA; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BASAL CELL CARCINOMA; BODY FLUID; CELL MEMBRANE; CELLULAR IMMUNITY; CHRONIC INFLAMMATION; CONDYLOMA ACUMINATUM; CYTOPLASM; DRUG TARGETING; GENE EXPRESSION; HOMEOSTASIS; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; INFECTION; INFLAMMATION; INNATE IMMUNITY; MULTIPLE SCLEROSIS; NEOPLASM; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FAMILY; REGULATORY MECHANISM; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MODELS, BIOLOGICAL; PEPTIDES; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; VASOACTIVE INTESTINAL PEPTIDE;

EID: 77950199408     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210790963841     Document Type: Review

References (222)

1. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388: 394-397
2. Slack JL, Schooley K, Bonnert TP, Mitcham JL, Qwarnstrom EE, Sims JE, et al. Identification of two major sites in the type I interleukin-1 receptor cytoplasmic region responsible for coupling to pro-inflammatory signaling pathways. J Biol Chem 2000; 275: 4670-4678
3. Barton GM, Kagan JC, Medzhitov R. Intracellular localization of Toll-like receptor 9 prevents recognition of self-DNA but facilitates access to viral DNA. Nat Immunol 2006; 7: 49-56.
4. Kajita E, Nishiya T, Miwa S. The transmembrane domain directs TLR9 to intracellular compartments that contain TLR3. Biochem Biophys Res Comun 2006; 343: 578-584
5. Takaoka A, Taniguchi T. Cytosolic DNA recognition for triggering innate immune responses. Adv Drug Deliv Rev 2008; 60: 847-857
6. Palm NW, Medzhitov R. Pattern recognition receptors and control of adaptive immunity. Immunol Rev 2009; 227: 221-233
7. Wolska A, Lech-Maranda E, Robak T. Toll-Like Receptors and their Role in Hematologic Malignancies. Curr Mol Med 2009; 9: 324-335
8. Marsh BJ, Williams-Karnesky RL, Stenzel-Poore MP. Toll-like receptor signaling in endogenous neuroprotection and stroke. Neuroscience 2009; 158: 1007-1020
9. Li M, Zhou Y, Feng G, Su SB. The critical role of toll-like receptor signaling pathways in the induction and progression of autoimmune diseases. Curr Mol Med 2009; 9: 365-374
10. Rifkin IR, Leadbetter EA, Busconi L, Viglianti G, Marshak-Rothstein A. Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev 2005; 204: 27-42.
11. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 783-801.
12. Jenkins KA, Mansell A. TIR-containing adaptors in Toll-like receptor signalling. Cytoquine 2009; March 3; doi:10.1016/j.cyto.2009.01.009.
13. Kenny EF, O'Neill LAJ. Signalling adaptors used by Toll-like receptors: an update. Cytokine 2008; 43: 342-349
14. Carty M, Goodbody R, Schröder M, Stack J, Moynagh PN, Bowie AG. The human adaptor SARM negatively regulates adaptor protein TRIF-dependent Toll-like receptor signaling. Nat Immunol 2006; 7: 1074-1081
15. Akashi-Takamura S, Miyake K. TLR accessory molecules. Curr Opin Immunol 2008; 20: 420-425
16. Kawai T, Akira S. TLR signaling. Semin Immunol 2007; 19: 24-32.
17. Noppert SJ, Fitzgerald KA, Hertzog PJ. The role of type I interferons in TLR responses. Immunol Cell Biol 2007; 85: 446-457
18. Kawai T, Akira S. Toll-like receptor and RIG-I-like receptor signaling. Ann NY Acad Sci 2008; 1143: 1-20.
19. Kawagoe T, Sato S, Matsushita K, Kato H, Matsui K, Kumagai Y, et al. Sequential control of Toll-like receptor-dependent responses by IRAK1 and IRAK2. Nat Immunol 2008; 9: 684-691
20. Wan Y, Xiao H, Affolter J, Kim TW, Bulek K, Chaudhuri S, et al. Interleukin-1 receptor-associated kinase 2 is critical for lipopolysaccharide- mediated post-transcriptional control. J Biol Chem 2009; 284: 10367-10375
21. Kobayashi K, Hernandez LD, Galán JE, Janeway CA, Jr, Medzhitov R, Flavell RA. IRAK-M is a negative regulator of Tolllike receptor signaling. Cell 2002; 110: 191-202.
22. Chen ZJ. Ubiquitin signalling in the NF-κB pathway. Nat Cell Biol 2005; 7: 758-765
23. Napolitano G, Mirra S, Monfregola J, Lavorgna A, Leonardi A, Ursini MV. NESCA: a new NEMO/IKKgamma and TRAF6 interacting protein. J Cell Physiol 2009; doi. 10.1002/jcp.21782.
24. O'Neill LA. When signaling pathways collide: positive and negative regulation of toll-like receptor signal transduction. Immunity 2008; 29: 12-20.
25. Park JE, Kim YI, Yi AK. Protein kinase D1 is essential for MyD88-dependent TLR signaling pathway. J Immunol 2009; 182: 6316-6327
26. Guiducci C, Ghirelli C, Marloie-Provost MA, Matray T, Coffman RL, Liu YJ, et al. PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation. J Exp Med 2008; 205: 315-322
27. Kaisho T, Tanaka T. Turning NF-κB and IRFs on and off in DC. Trends Immunol 2008; 29: 329-336
28. Häcker H, Redecke V, Blagoev B, Kratchmarova I, Hsu LC, Wang GG, et al. Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature 2006; 439: 204-207
29. Oganesyan G, Saha SK, Guo B, He JQ, Shahangian A, Zarnegar B, et al. Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response. Nature 2006; 439: 208-211
30. Honda K, Taniguchi T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 2006; 6: 644-658
31. Krishnan J, Selvarajoo K, Tsuchiya M, Lee G, Choi S. Toll-like receptor signal transduction. Exp Mol Med 2007; 39: 421-438
32. Beutler B. Microbe sensing, positive feedback loops, and the pathogenesis of inflammatory diseases. Immunol Rev 2009; 227: 248-263
33. Joffre O, Notle MA, Spörri R, Reis e Sousa C. Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol Rev 2009; 227: 234-247
34. Crozat K, Vivier E, Dalod M. Crosstalk between components of innate immune system: promoting anti-microbial defenses and avoiding immunopathologies. Immunol Rev 2009; 227: 129-149
35. Kluwe J, Mencin A, Schawabe RF. Toll-like receptors, wound healing and carcinogenesis. J Mol Med 2009; 87: 125-138
36. Karin M, Lawrence T, Nizet V.Innate Immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 2006; 124: 823-835
37. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436-444
38. Kim S, Takashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009; 457: 102-107
39. Rakoff-Nahoum S, Hao L, Medzhitov R. Role of toll-like receptors in spontaneous commensal-dependent colitis. Immunity 2006; 25: 189-191
40. Mencin A, Kluwe J, Schwabe RF. Toll-like receptors as targets in chronic liver disease. Gut 2009; 58: 704-720
41. Goldman M. Translational mini-review series on toll-like receptors: toll-like receptors ligand as novel pharmaceuticals for allergic disorders. Clin Exp Immunol 2007; 147: 208-216
42. Van Duin D, Mohanty S, Thomas V, Ginter S, Montgomery RR, Fikrig E, et al. Age associated defect in human TLR1/2 function. J Immunol 2007; 178: 970-975
43. Poltorak A, He X, Smirnova I, Liu MY, Van Fuel C, Due X, et al. Defective LPS signalling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998; 282: 2085-2088
44. Lorenz E, Mira JP, Frees KL, Scwartz DA. Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med 2002; 162: 1028-1032
45. Janssen S, Beyaert R. Role of Toll-like receptors in pathogen recognition. Clin Microbiol Rev 2003; 16: 637-646
46. Mukhopadhyay S, Herre J, Brown GD, Gordon S. The potential of Toll-Like receptors to collaborate with other innate immune receptors. Immunology 2004; 112: 521-530
47. Bowie AG. Translation mini-review series on toll-like receptors. Recent advances in understanding the role of toll-like receptors in anti-viral immunity. Clin Exp Immunol 2007; 147: 217-226
48. Lawton JA, Ghosh P. Novel therapeutic strategies based on toll-like receptor signalling. Curr Opin Chem Biol 2003; 7: 446-451
49. Saturnino SF, Andrade MV. Toll-like receptors, new horizons in sepsis. Curr Mol Med 2007; 7: 522-531
50. Wang T, Town T, Alexopoulou L, Anderson JF, Fikrig E, Flavell RA. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat med 2004; 10: 1366-1373
51. Coban C, Ishii KJ, Kawai T, Hemmi H, Sato S, Uematsu S, et al. Toll-receptor 9 mediates innate immune activation by the malaria pigment hemozoin. J Exp Med 2005; 201: 19-25.
52. Fukusaki T, Ohara N, Hara Y, Yoshimura A, Yoshiura K. Evidence for association between a toll-like receptor 4 gene polymorphism and moderate/severe periodontitis in the Japanese populatios. J Peridontal Res 2007; 42: 541-545
53. Netea MG, Sutmuller R, Hermann C, Van der Graaf CA, Van der Meer JW, van Krieken JH. Toll-like receptor 2 suppresses immunity against Candida albicans through induction of IL-10 and regulatory T cells. J Immunol 2004; 172: 3712-3718
54. Chang JH, McCluskey PJ, Wakefield D. Toll-like receptors in ocular immunity and the immunopathogenesis of inflammatory eye disease. Br J Ophthalmol 2006; 90: 103-108
55. Papadimitraki ED, Bertsias GK, Boumpas DT. Toll-like receptors and autoimmunity: A critical appraisal. J Autoimmun 2007; 29: 310-318
56. Zhang D, Zhang G, Hayden MS, Greenblatt MB, Bussey C, Flavel RA, et al. A toll-like receptor prevents infection by uropathogenic bacteria. Science 2004; 303: 1522-1526
57. Bhattacharjee RN, Akira S. Toll-like receptor 9 signaling for therapeutic use. Mini Rev Med Chem 2006; 6: 287-291
58. Eder W, Klimecki W, Yu L, von Mutius E, Riedler J, Braun-Fahrländer C, et al. Toll-like receptor 2 as a major gene for asthma in children of European farmers. J Allergy Clin Immunol 2004; 113: 482-488
59. Tantisira K, Klimecki WT, Lazarus R, Palmer LJ, Raby BA, Kwiatkowski DJ, et al. Toll-like receptor 6 gene (TLR6): single-nucleotide polymorphism frequencies and preliminary association with the diagnosis of asthma. Genes Immun 2004; 5: 343-346
60. Phipps S, Lam CE, Foster PS, Matthaei KI. The contribution of Toll-like receptors to the pathogenesis of asthma. Immunol Cell Biol 2007; 85: 463-470
61. Revets H, Pynaert G, Grooten J, De Baetselier P. Lipoprotein, a TLR2/4 ligand modulates Th2-driven allergic immune responses. J Immunol 2005; 174: 1097-1103
62. Hoffjan S, Stemmler S, Parwez Q, Petrasch-Parwez E, Arinir U, Rohde G, et al. Evaluation of the Toll-like receptor 6 Ser249Pro polymorphism in patients with asthma, atopic dermatitis and chronic obstructive pulmonary disease. BMC Med Genet 2005; 6: 34.
63. Lazarus R, Raby BA, Lange C, Silverman EK, Kwiatkowski DJ, Vercelli D, et al. Toll-like receptor 10 genetic variation in association with asthma in two independent samples. Am J Respir Crit Care Med 2004; 170: 594-600.
64. Sarir H, Henricks PA, van Houwelingen AH, Nijkamp FP, Folerts G. Cell, mediators and toll-like receptors in COPD. Eur J Pharmacol 2008; 585: 346-353
65. Hansen BS, Hussain RZ, Lovett-Racke AE, Thomas JA, Racke MK. Multiple toll-like receptor agnist acts as potent adjuvants in the induction of autoimmunity. J Neuroimmunol 2006; 172: 1256-1265
66. Marta M, Andersson A, Isaksson M, Kümpe O, Lobell A. Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis. Eur J Immunol 2008; 38: 565-575
67. Prinz M, Garbe F, Schmidt H, Mildner A, Gutcher I, Wolter K, et al. Innate immunity mediated by TLR9 modulated pathogenicity in an animal model of multiple sclerosis. J Clin Invest 2006; 116: 456-464
68. Atkinson TJ. Toll-like receptors, transduction-effector pathways, and disease diversity: evidence of an immunobiological paradigm explaining all human illness. Int Rev Immunol 2008; 27: 255-281.
69. Hawn TR, Wu H, Grossman JM, Hahn BH, Tsao BP, Aderem A. A stop codon polymorphism of toll-like receptor 5 is associated with resistance to systemic lupus erythromatosus. Proc Natl Acad Sci USA 2005; 102: 10593-10597
70. Pisitkun P, Deane JA, Difilippantonio MJ, Tarasenko T, Satterthwaite AB, Bolland S. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 2006; 312: 1669-1672
71. Ehlers M, Ravetch JV. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Trends Immunol 2007; 28: 74-79
72. Lien E, Zipris D. The role of toll-like receptor pathways in the mechanism of type I diabetes. Curr Mol Med 2009; 9: 52-68.
73. Nair A, Wolter TR, Meyers AJ, Zipris D. Innate immune pathway in virus-induced autoimmune diabetes. Ann NY Acad Sci USA 2008; 1150: 139-142
74. Marsland BJ, Nembrini C, Grun K, Reissmann R, Kurrer M, Leipner C, et al. TLR ligands act directly upon T cells to restore proliferation in the absence of protein kinase C-theta signalling and promote autoimmune myocarditis. J Immunol 2007; 178: 3466-3473
75. Lin E, Freedman JE, Beaulieu LM. Innate immunity and toll-like receptor antagonists: a potential role in the treatment of cardiovascular disease. Cardiovasc Ther 2009; 27: 117-123
76. Frantz S, Ertl G, Bauersachs J. Mechanisms of disease: toll-like receptors in cardiovascular disease. Nat Clin Pract Cardiovasc Med 2007; 4: 444-454
77. Lang KS, Georgiev P, Recher M, Navarini AA, Bergthaler A, Heikenwalder M, et al. Immunoprivileged status of the liver controlled by toll-like receptor 3 signaling. J Clin Invest 2006; 116: 2456-2463
78. Yamazaki K, Suzuki K, Yamada T, Takeshita F, Matsumoto M, Mitsuhashi T, et al. Suppression of iodide uptake of thyroid hormone synthesis with stimulation of the type I interferon system by double-stranded ribonucleic acid in cultured human thyroid follicles. Endocrinology 2007; 148: 3226-3235
79. Barrat FJ, Coffman RL. Development of TLR inhibitors for the treatment of autoimmune disease. Immunol Rev 2008; 223: 271-283
80. Gilliet M, Lande R. Anti-microbial peptides and self-DNA in autoimmune skin inflammation. Curr Opin Immunol 2008; 20: 401-407
81. Steenholdt C, Andresen L, Pedersen G, Hansen A, Brynskov J. Expression and function of toll-like receptor 8 and tollip in colonic epithelial cells from patients with inflammatory bowel disease. Scand J Gastroenterol 2009; 44:195-204.
82. Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000; 68: 7010-7017
83. Netea MG, Kullberg BJ, de Jong B, Franke T, Sprong TH, Naber JP, et al. NOD2 mediates anti-inflammatory signals induced by TLR2 ligands: implications for Crohn's disease. Eur J Immunol 2004; 34: 2052-2059
84. Pierik M, Joosens S, Van Steen K, Van Schverbeek N, Vlietinick R, Rutgeerts P, et al. Toll-like receptor -1, -2, -6 polymorphisms influence disease extension in inflammatory bowel disease. Inflamm Bowel Dis 2006; 12:1-8.
85. Hong J, Leany E, Fraser AG, Merriman TR, Vishnu P, Krissansen GM. TLR2, TLR4 and TLR9 polymorphisms and Crohn's disease in a New Zealand Caucasian cohort. J Gastroenterol Hepatol 2007; 22: 1760-1766
86. Vijay-kumar M, Aitken JD, Gewirtz AT. Toll-like receptor 5 protecting the gut from enteric microbes. Semin Immunopathol 2008; 30: 11-21.
87. Brentano F, Kyburtz D, Gay S. Toll-like receptors and rheumatoid arthritis. Methods Mol Biol 2009; 517: 329-343
88. Ospelt C, Brentano F, Bergel Y, Stanck J, Kolling C, Takk PP, et al. overexpression of toll-like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: toll-like receptor expression in early and longstanding arthritis. Arthritis Rheum 2008; 58: 3684-3692
89. Liu B, Yang J, Dai R, Medzhitov MA, Freudenberg PL, Zhang PL, et al. TLR4 up-regulation at protein or gene level is pathogenic for lupus-like autoimmune disease. J Immunol 2006; 177: 6880-6888
90. Benigni A, Caroli C, Longaretti L, Gagliardini E, Zoja C, Moioli D, et al. Involvement of renal tubular toll-like receptor 9 in the development of tubulointerstitial injury in systemic lupus. Arthritis Rheum 2007; 56: 1569-1578
91. Anders H, Schlöndorff D. Toll-like receptor: emerging concepts in kidney disease. Curr Opin Nephrol Hypertens 2007; 16: 177-183
92. Zeromski J, Mozer-Lisewska I, Kaczmarek M. Significance of toll-like receptors expression in tumor growth and speading: a short review. Cancer Microenviron 2008; 1: 37-42.
93. Wolska A, Lech-Maranda E, Robak T. Toll-like receptors and their role in carcinogenesis and anti-tumor treatment. Cell Mol Biol Lett 2009; 14: 248-272
94. Paulus CM, Kaiser A, Wresinsli C, Hinrichs CS, Cassard L, Boni A, et al. Toll-like receptors in tumor immunotherapy. Clin Cancer Res 2007; 13: 5280-5289
95. Gangloff SC, Guenounou M. Toll-like receptors and immune response in allergic disease. Clin Rev Allergy Immunol 2004; 26: 115-125
96. Velasco G, Campo M, Manrique OJ, Bellou A, He H, Arestides RS, et al. Toll-like receptor 4 or 2 agonists decrease allergic inflammation. Am J Respir Cell Mol Biol 2005; 32: 218-224
97. Bullens DM, Ceuppen JL. Influence of toll-like receptor ligands on the dendritic cell-T cell interactions, therapeutic options for allergic diseases? Mini-review. Inflamm Allergy Drug Targets 2008; 7: 211-216
98. Van Duin D, Shaw AC. Toll-like receptors in older adults. J Am Geriatr Sox 2007; 55: 1438-1444
99. Ishihara S, Rumi MAK, Ortega-Cava CF, Kazumori H, Kadowaki Y, Ishimura N, et al. Therapeutic targeting of Toll-like receptors in gastrointestinal inflammation. Curr Pharm Des 2006; 12: 4215-4228.
100. Ishii KJ, Uematsu S, Akira S. "Toll" gates for future immunotherapy. Curr Pharm Des 2006; 12: 4135-4142
101. Romagne F. Current and future drugs targeting one class of innate immunity receptors: the Toll-like receptors. Drug Discov Today 2007; 12: 80-87.
102. Tse K, Horner AA. Update on toll-like receptor-directed therapies for human disease. Ann Rheum Dis 2007; 66: 77-80.
103. Parkinson T. The future of toll-like receptors therapeutics. Curr Opin Mol Ther 2008; 10: 21-31.
104. Horner AA, Ronhaghy A, Cheng PM, Nguyen MD, Cho HJ, Broide D, et al. Immunostimulatory DNA is a potent mucosal adjuvant. Cell Immunol 1998; 190: 77-82.
105. Van Duin D, Medzhitov R, Show AC. Triggering TLR signalling in vaccination. Trends Immunol 2006; 27: 49-55.
106. Halperin SA, Dobson S, McNeil S, Langley JM, Smith B, McCall-Sani R, et al. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. Vaccine 2006; 24: 20-26.
107. Liew F, Xu D, Brint EK, O' Neill AJ. Negative regulation of Toll-like receptor-mediated immune responses. Nature 2006; 5: 446-458
108. LeBourder, E, Rey-Nores JE, Rushmere NK, Grigorov M, Lawn SD, Affolter M, et al. Soluble forms of Toll-like receptors (TLR)2 capable of modulating TLR2 signaling are present in human plasma and breast milk. J Immunol 2003; 171: 6680-6689
109. Iwami, KI, Matsuguchi T, Masuda A, Kikuchi T, Musikacharoen T, Yoshikai Y. Cutting edge: naturally occurring soluble form of mouse toll-like receptor 4 inhibits lipopolysaccharide signalling. J Immunol 2000; 165: 6682-6686
110. Brint EK, Xu D, Liu H, Dunne A, McKenzie AN, O'Neill LA, et al. ST2 is an inhibitor of interleukin 1 receptor and toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat Immunol 2004; 5: 373-379
111. Qin J, Quian Y, Yao J, Grace C, Li X. SIGIRR inhibits interleukin-1 receptor- and toll-like receptor 4- mediated signalling through different mechanisms. J Biol Chem 2005; 280: 25233-25241
112. Bulek K, Swaidani S, Qin J, Lu Y, Gulen MF, Herjan T, et al. The essential role of single Ig IL-1 receptor-related molecule/toll IL-1R8 in regulation of Th2 immune response. J Immunol 2009; 182: 2601-2609
113. Divanovik S, Trompette A, Atabani SF, Madan R, Golenbock DT, Visintin A, et al. Negative regulation of toll-like receptor 4 signaling by the toll-like receptor homolog RP105. Nat Immunol 2005; 6: 571-578
114. Diehl GE, Yue HH, Hsieh K, Kuang AA, Ho M, Morici LA, et al. TRAIL-R as a negative regulator of innate immune cell responses. Immunity 2004; 21: 877-889
115. Wang J, Hu Y, Deng WW, Sun B. Negative regulation of toll-like receptor signalling pathway. Microbes Infect 2009; 11: 321-327
116. Burns K, Janssens S, Brissoni B, Olivos N, Beyaert R, Tschopp J. Inhibition of interleukin 1 receptor/toll-like receptor signalling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J Exp Med 2003; 197: 263-268
117. Lang T, Mansell A. The negative regulation of toll-like receptor and associated pathways. Immunol Cell Biol 2007; 85: 425-434
118. O'Neill LA. DisSARMing toll-like receptor signaling. Nat Immunol 2006; 7: 1023-1025
119. Wang T, Chuang TH, Ronni T, Gu S, Du YC, Cai H, et al. Flightless I homolog negatively modulates the TLR pathway. J Immunol 2006; 176: 1355-1362
120. Hardy MP, O'Neill LA. The murine IRAK2 gene encodes four alternatively spliced isoforms, two of which are inhibitory. J Biol Chem 2004; 279: 27699-27708
121. Takeshita F, Ishii KJ, Kobiyama K, Kojima Y, Coban C, Sasaki S, et al. TRAF4 acts as a silencer in TLR-mediated signalling through the association with TRAF6 and TRIF. Eur J Immunol 2005; 35: 2477-2485
122. Zhang G, Ghosh S. Negative regulation of toll-like receptor-mediated signalling by Tollip. J Biol Chem 2002; 277: 7059-7065
123. Boone DL, Turner EE, Lee EG, Ahmad RC, Wheeler MT, Tsui C, et al. The ubiquitin-modifying enzyme A20 is required for termination of toll-like receptor responses. Nat Immunol 2004; 5: 1052-1060
124. Fan H, Luttrell LM, Tempel GE, Senn JJ, Halushka PV, Cook JA. β-arrestins 1 and 2 differentially regulate LPS-induced signalling and pro-inflammatory gene expression. Mol Immunol 2007; 44: 3092-3099
125. Wullaert A, Verstrepen L, Van Huffel S, Adib-Conquy M, Cornelis S, Kreike M, et al. LIND/ABIN-3 is a novel lipopolysaccharide-inducible inhibitor of NF-κB activation. J Biol Chem 2007; 282: 81-90.
126. Mashima R, Saek K, Aki D, Minoda Y, Takaki H, Kobayashi T, et al. FLN29, a novel interferon- and LPS-inducible gene acting as a negative regulator of toll-like receptor signalling. J Biol Chem 2005; 280: 41289-41297
127. Yoshida H, Jono H, Kai H, Li LD. The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 and TRAF7. J Biol Chem 2005; 280: 41111-41121
128. An H, Zhao W, Hou J, Zhang Y, Xie Y, Xu H, et al. SHP-2 phosphatase negatively regulates the TRIF adaptor proteindependent type I interferon and proinflammatory cytokine production. Immunity 2006; 25: 918-929
129. Ryo A, Suizu F, Yoshida Y, Perrem K, Liou YC, Wulf G, et al. Regulation of NF-κB signalling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol Cell 2003; 12: 1413-1426
130. Saitoh T, Tun-Kyi A, Ryo A, Yamamoto M, Finn G, Fujita T, et al. Negative regulator of interferon-regulatory factor 3-dependent innate antiviral response by the prolylisomerase Pin1. Nat Immunol 2006; 7: 598-605.
131. Fukao T, Koyasu S. PI3K and negative regulation of TLR signalling. Trends Immunol 2003; 24: 358-363
132. Gilchrist M, Thorsson V, Li B, Rust AG, Korb M, Kennedy K, et al. Systems biology approaches identify ATF3 as a negative regulator of toll-like receptor-4. Nature 2006; 441: 173-178
133. Carmody RJ, Ruan Q, Palmer S, Hilliard B, Chen YH. Negative regulation of toll-like receptor signalling by NF-κB p50 ubiquitination blockade. Science 2007; 317: 675-678
134. Beutler B. Interferences, questions and possibilities in toll-like receptors signalling. Nature 2004; 430: 257-263
135. Foster SL, Medzhitov R. Gene-specific control of the TLR-induced inflammatory response. Clin Immunol 2009; 130: 7-15.
136. Iwasaki Y, Taguchi T, Nishiyama M, Asai M, Yoshida M, Kambayashi M, et al. Lypopolysaccharide stimulates proopiomelanocortin gene expression in AtT20 corticotroph cells. Endocr J 2008; 55: 285-290
137. Bornstein S, Zacharowski P, Schumann R, Barthel A, Tran N, Papewalis C, et al. Impaired adrenal stress response in toll-like receptor 2-deficient mice. Proc Natl Acad Sci USA 2004; 101: 16695-16700
138. Zacharowski K, Zararowski P, Koch A, Baban A, Tran N, Berkels R, et al. Toll-like receptor 4 plays a crucial role in the immune-adrenal response to systemic inflammatory response syndrome. Proc Natl Acad Sci USA 2006; 103: 6392-6397
139. Palazzo M, Balsari A, Rossini A, Selleri S, Calcaterra C, Gariboldi S, et al. Activation of enteroendocrine cells via TLRs induces hormone, chemokine, and defensin secretion. J Immunol 2007; 178: 4296-4303
140. Sternberg E. Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nat Rev Immunol 2006; 6: 318-329
141. Gonzalez-Rey E, Delgado M. Anti-inflammatory neuropeptide receptors: new therapeutic targets for immune disorders? Trends Pharmacol Sci 2007; 28: 482-491
142. Brenner S, Prösch S, Schenke-Layland K, Riese U, Gausmann U, Platzer C. cAMP-induced interleukin-10 promoter activation depends on CAAT/enhancer-binding protein expression and monocytic differentiation. J Biol Chem 2003; 278: 5597-5604
143. Park P, Huang H, McMullen M, Bryan K, Nagy L. Activation of cyclic-AMP response element binding protein contributes to adiponectin-stimulated interleukin-10 expression in raw 264.7 macrophages. J Leukoc Biol 2008; 83: 1258-1266
144. Chassin C, Hornef M, Bens M, Lotz M, Goujon J-M, Vimont S, et al. Hormonal control of the renal immune response and antibacterial host defence by arginine vasopressin. J Exp Med 2007; 204: 2837-2852
145. Harzenetter M, Novotny A, Gais P, Molina C, Altmayr F, Holzmann B. Negative regulation of TLR responses by the neuropeptide CGRP Is mediated by the transcriptional repressor ICER. J Immunol 2007; 179: 607-615
146. Yoon SW, Goh SH, Chun JS, Cho EW, Lee MK, Kim KL, et al. α-melanocyte-stimulating hormone inhibits lipopolysaccharide induced tumor necrosis factor-α production in leukocytes by modulating protein kinase A, p38 kinase, and nuclear factor κB signaling pathways. J Biol Chem 2003; 278: 32914-32920
147. DeWire S, Ahn S, Lefkowitz R, Shenoy S. β-arrestins and cell signaling. Annu Rev Physiol 2007; 69: 483-510.
148. Di Fiore P, Polo S, Hofmann K. When ubiquitin meets ubiquitin receptors: a signalling connection. Nat Rev Mol Cell Biol 2003; 4: 491-497
149. Witherow D, Garrison T, Miller W, Lefkowitz R. β-Arrestin inhibits NF-κB activity by means of its interaction with the NF-κB inhibitor IkBα. Proc Natl Acad Sci USA 2004; 101: 8603-8607
150. Gao H, Sun Y, Wu Y, Luan B, Wang Y, Qu B, et al. Identification of β- arrestin2 as a G protein-coupled receptor-stimulated regulator of NF-κB pathways. Mol Cell 2004; 14: 303-317
151. Wang Y, Tang Y, Teng L, Wu Y, Zhao X, Pei G. Association of β-arrestin and TRAF6 negatively regulates toll-like receptorinterleukin 1 receptor signaling. Nat Immunol 2006; 7: 139-147
152. Taylor A. The immunomodulating neuropeptide alpha-melanocyte-stimulating hormone (α-MSH) suppresses LPS-stimulated TLR4 with IRAK-M in macrophages. J Neuroimmunol 2005; 162: 43-50.
153. Tsatsanis C, Androulidaki A, Alissafi T, Charalampopoulos I, Dermitzaki E, Roger T, et al. Corticotropin-releasing factor and the urocortins induce the expression of TLR4 in macrophages via activation of the transcription factors PU.1 and AP-1. J Immunol 2006; 176: 1869-1877
154. Said SI, Mutt V. Potent peripheral splanchnic vasodilator peptide from normal gut. Nature 1970; 225: 863-864
155. Davidson A, Moddy TW, Gozes I. Regulation of VIP expression in general. J Mol Neurosci 1996; 7: 99-110.
156. Bellinger DL, Lorton D, Horn L, Brouxhon S, Felten SY, Felten DL. Vasoactive intestinal polypeptide (VIP) innervation of rat thymus and lymph nodes. Peptides 1997; 8: 1139-1149
157. Cutz E, Chan W, Track NS, Gooth A, Said SI. Release of vasoactive intestinal polypeptide in mast cells by histamine liberators. Nature 1978; 275: 661-662
158. O'Dorisio MS, O'Dorisio TM, Cataland S, Balcerzak SP. Vasoactive intestinal polypeptide as a biochemical marker for polymorphonuclear leukocytes. J Lab Clin Med 1980; 96: 666-672
159. Weinstock JV, Blum AM. Detection of vasoactive intestinal peptide and localization of its mRNA within granulomas of murine schistosomiasis. Cell Immunol 1990; 125: 291-300.
160. Gomariz RP, Lorenzo MJ, Cacicedo L, Zapata AG. Demonstration of immunoreactive vasoactive intestinal peptide (IR-VIP) and somatostatin (IR-SOM) in rat thymus. Brain Behav Immun 1990; 4: 151-161
161. Gomariz RP, Delgado M, Naranjo JR, Mellstrom B, Tormo A, Mata F, et al. VIP gene expression in rat thymus and spleen. Brain Behav Immun 1992; 7: 271-278
162. Leceta J, Martinez J, Delgado M, Garrido E, Gomariz RP. Lymphoid cells subpopulations containing vasoactive intestinal peptide. Peptides 1994; 15: 791-797
163. Martínez C, Delgado M, Abad C, Gomariz RP, Ganea D, Leceta J. Regulation of VIP production and secretion by murine lymphocytes. J Neuroimmunol 1999; 93: 126-138
164. Harmar AJ, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna JR, et al. Nomenclature of receptors for vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP). Pharmacol Rev 1998; 50: 625-627
165. Delgado M, Abad C, Martinez C, Juarranz Y, Arranz A, Gomariz RP, et al. Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases. J Mol Med 2002; 80: 16-24.
166. Gomariz RP, Martinez C, Abad C, Leceta J, Delgado M. Immunology of VIP: a review and therapeutical perspectives. Curr Pharm Des 2001; 7: 89-111.
167. Delgado M, Pozo D, Ganea D. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev 2004; 56: 249-290
168. Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med 2001; 7: 563-568
169. Abad C, Martínez C, Juarranz MG, Arranz A, Leceta J, Delgado M, et al. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid model of Crohn's disease. Gastroenterology 2003; 124: 961-971
170. Li H, Mei Y, Wang Y, Xu L. Vasoactive intestinal peptide suppressed experimental autoimmune encephalomyelitis by inhibiting T helper 1 responses. J Clin Immunol 2006; 26: 430-437
171. Lodde BM, Mishiba F, Wang J, Cotrim AP, Afiore S, Tak PP, et al. Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome. Ann Rheum Dis 2006; 65: 195-200.
172. Rosignoli F, Torroba M, Juarranz Y, García-Gómez M, Martínez C, Gomariz RP, et al. VIP and tolerance induction in autoimmunity. Ann NY Acad Sci USA 2006; 1070: 525-530
173. Gonzalez-Rey E, Chorny A, Delgado M. Regulation of immune tolerance by anti-inflammatory neuropeptides. Nat Rev Immunol 2007; 7: 52-63.
174. Gomariz RP, Arranz A, Juarranz Y, Gutierrez-Cañas I, García-Gómez M, Leceta J, et al. Regulation of TLR expression, a new perspective for the role of VIP in immunity. Peptides 2007; 28: 1825-1832
175. Hart OM, Athie-Morales V, O'Connor GM, Gardiner CM. TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production. J Immunol 2005; 175: 1636-1642
176. Kobayashi M, Kweon MN, Kuwata H, Schreiber RD, Kiyono H, Takeda K, et al. Toll-like receptor-dependent production of IL-12p40 causes chronic enterocolitis in myeloid cell-specific Stat3-deficient mice. J Clin Invest 2003; 111: 1297-1308
177. Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995; 182: 1281-1290
178. Neurath MF, Finotto S, Glimcher LH. The role of Th1/Th2 polarization in mucosal immunity. Nat Med 2002; 8: 567-573
179. Gomariz RP, Arranz A, Abad C, Torroba M, Martínez C, Rosignoli F, et al. Time-course of toll-like receptors 2 and 4 in inflammatory bowel disease and homeostatic effect of VIP. J Leukoc Biol 2005; 78: 491-502.
180. Arranz A, Abad C, Juarranz Y, Torroba M, Rosignoli F, Leceta J, et al. Effect of VIP on TLR2 and TLR4 expression in lymph node immune cells during TNBS-induced colitis. Ann NY Acad Sci 2006; 1070: 129-134
181. Arranz A, Abad C, Juarranz Y, Leceta J, Martínez C, Gomariz RP. Vasoactive intestinal peptide as a healing mediator in Crohn' disease. Neuroimmunomodulation 2008; 15: 46-53.
182. Musikacharoen T, Matsuguchi T, Kikuchi T, Yoshikai Y. NF-κB and STAT 5 play important roles in the regulation of mouse tolllike receptor 2 gene expression. J Immunol 2001; 166: 4516-4524
183. Delgado M, Muñoz-Elias EJ, Kan Y, Gozes I, Fridkin M, Brenneman DE, et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor α transcriptional activation by regulating nuclear factor-κB and cAMP response element-binding protein/c-Jun. J Biol Chem 1998; 273: 31427-31436
184. Juarranz Y, Abad C, Martínez C, Arranz A, Gutierrez-Cañas I, Rosignoli F, et al. Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res Ther 2005; 7: 1034-1045
185. Arranz A, Juarranz Y, Leceta J, Gomariz RP, Martínez C. VIP balances innate and adaptive immune responses induced by specific stimulation of TLR2 and TLR4. Peptides 2008; 29: 948-956
186. McCormack G, Moriarty D, O'Donoghue DP, McCormick PA, Sheahan K, Baird AW. Tissue cytokine and chemokine expression in inflammatory bowel disease. Inflamm Res 2001; 50: 491-495
187. Erard F, Ryffel B. Toll-like receptor-potential drug targets in infectious disease. Infect Disord Drug Targets 2008; 8: 221-231
188. Xu D, Komai-Koma M, Liew FY. Expression and function of toll-like receptor on T cells. Cell Immunol 2005; 233: 85-89
189. Kabelitz D. Expression and function of toll-like receptors in T lymphocytes. Curr Opin Immunol 2007; 19: 39-45.
190. Liu H, Komai-Koma M, Xu D, Liew FY. Toll-like receptor 2 signaling modulates the functions of CD4+CD25+ regulatory T cells. Proc Natl Acad Sci USA 2006; 103: 7048-7053
191. Caramalho I, Lopes-Carvalho T, Ostler D, Zelenay S, Haury M, Demengeot J. Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J Exp Med 2003; 197: 403-411
192. Arciszewski MB, Sand E, Ekblad E. Vasoactive intestinal peptide rescues cultured rat myenteric neurons from lipopolysaccharide induced cell death. Regul Pept 2008; 146: 218-223
193. Ekblad E, Bauer AJ. Role of vasoactive intestinal peptide and inflammatory mediators in enteric neuronal plasticity. Neurogastroenterol Motil 2004; 16: 123-128
194. Sandgren K, Lin Z, Fex-Svenningsen A, Ekblad E. Vasoactive intestinal peptide and nitric oxide promote survival of adult rat myenteric neurons in culture. J Neurosci Res 2003; 72: 592-602.
195. Gozes I, Brenneman DE. A new concept in the pharmacology of neuroprotection. J Mol Neurosci 2000; 14: 61-68
196. Ekblad E, Sjuve R, Arner A, Sundler F. Enteric neuronal plasticity and a reduced number of interstitial cells of Cajal in hypertrophic rat ileum. Gut 1998; 42: 836-844
197. Arciszewski MB, Pierzynowski S, Ekblad E. Lipopolysaccharide induces cell death in cultured porcine myenteric neurons. Dig Dis Sci 2005; 50: 1661-1668
198. Arranz A, Androulidaki A, Zacharioudaki V, Martínez C, Margioris AN, Gomariz RP, et al. Vasoactive intestinal peptide suppresses toll-like receptor 4 expression in macrophages via Akt1 reducing their responsiveness to lipopolysaccharide. Mol Immunol 2008; 45: 2970-2980
199. Roger T, Miconnet I, Schiesser AL, Kai H, Miyake K, Calandra T. Critical role for Ets, AP-1 and GATA-like transcription factors in regulating mouse Toll-like receptor 4 (Tlr4) gene expression. Biochem J 2005; 387: 355-365
200. Guha M, Mackman N. The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J Biol Chem 2002; 277: 32124-32132
201. Nomura F, Akashi S, Sakao Y, Sato S, Kawai T, Matsumoto M, et al. Cutting edge: endotoxin tolerance in mouse peritoneal macrophages correlates with downregulation of surface toll-like receptor 4 expression. J Immunol 2000; 164: 3476-3479
202. West MA, Heagy W. Endotoxin tolerance: a review. Crit Care Med 2002; 30: S64-S73.
203. Herrera JL, Gonzalez-Rey E, Fernández-Montesinos R, Quintana FJ, Najmanovich R, Pozo D. Toll-like receptor stimulation differentially regulates vasoactive intestinal peptide type 2 receptor in macrophages. J Cell Mol Med 2009; January 16; doi. 10.111/j1582-4934.2008.00662.
204. Gutierrez-Cañas I, Juarranz Y, Santiago B, Arranz A, Martínez C, Galindo M, et al. VIP down-regulates TLR4 expression and TLR4-mediated chemokine production in human rheumatoid synovial fibroblasts. Rheumatology 2006; 45: 527-532
205. Brentano F, Kyburz D, Schorr O, Gay R, Gay S. The role of Toll-like receptor signalling in the pathogenesis of arthritis. Cell Immunol 2005; 233: 90-96
206. Radstake TR, Roelofs MF, Jenniskens YM, Oppers-Walgreen B, van Riel RL, Barrera P, et al. Expression of toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-γ. Arthritis Rheum 2004; 50: 3856-3865
207. Kyburz D, Rethage J, Seibl R, Lauener R, Gay RE, Carson DA, et al. Bacterial peptidoglycans but not CpG oligodeoxynucleotides activate fibroblasts by toll-like receptor signaling. Arthritis Rheum 2003; 48: 642-650
208. Proost P, Verpoest S, Van de Borne K, Schutyser E, Struyf S, Put W, et al. Synergistic induction of CXCL9 and CXCL11 by toll-like receptor ligands and interferon-γ in fibroblasts correlates with elevated levels of CXCR3 in septic arthritis synovial fluids. J Leukoc Biol 2004; 75: 777-784
209. Seibl R, Birchler T, Loeliger S, Hossle JP, Gay RE, Saurenmann T, et al. Expression and regulation of toll-like receptor 2 in rheumatoid arthritis synovium. Am J Pathol 2003; 162: 1221-1227
210. Burman A, Haworth O, Hardie DL, Amft EN, Siewrt C, Jackson DG, et al. A chemokine-dependent stromal induction mechanisms for aberrant lymphocyte accumulation and compromised lymphatic return in rheumatoid arthritis. J Immunol 2005; 174: 1693-1700
211. Juarranz MG, Santiago B, Torroba M, Gutierrez-Cañas I, Palao G, Galindo M, et al. Vasoactive intestinal peptide modulates pro-inflammatory mediator synthesis in osteoarthritic and rheuma-toid synovial cells. Rheumatology 2004; 43: 416-422
212. Arranz A, Gutierrez Cañas I, Carrión M, Juarranz Y, Pablos JL, Martínez C, et al. VIP reverses the expression profiling of TLR4-stimulated signaling pathway in rheumatoid arthritis synovial fibroblasts. Mol Immunol 2008; 45: 3065-3073
213. Delgado M, Leceta J, Abad C, Martínez C, Ganea D, Gomariz RP. Shedding of membrane-bound CD14 from lipopolysaccharide-stimulated macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide. J Neuroimmunol 1999; 99: 61-71.
214. Juarranz Y, Gutierrez-Cañas I, Santiago B, Carrión M, Pablos JL, Gomariz RP. Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts. Arthritis Rheum 2008; 58: 1086-1095
215. Delgado M, Robledo G, Rueda B, Varela N, O'Valle F, Hernández- Cortés P, et al. Genetic association of vasoactive intestinal peptide receptor with rheumatoid arthritis: altered expression and signal in immune cells. Arthritis Rheum 2008; 58: 1010-1019.
216. Foster N, Lea SR, Preshaw PM, Taylor JJ. Vasoactive intestinal peptide inhibits up-regulation of human monocytes TLR2 and TLR4 by LPS and differentiation of monocytes to macrophages. J Leukoc Biol 2007; 81: 893-903.
217. Rehli M. Of mice and men: species variation of toll-like receptor variation. Trends Immunol 2002; 23: 375-378
218. Rehli M, Poltorak A, Schwarzfischer I, Krause SW, Andreesen R, Beutler B. PU.1 and interferon consensus sequence-binding protein regulate the myeloid expression of the human toll-like receptor 4 gene. J Biol Chem 2000; 275: 9773-9781
219. Haehnel V, Schwarzfischer I, Fenton MJ, Rehli M. Transcriptional regulation of the human Toll-like receptor 2 gene in monocytes and macrophages. J Immunol 2002; 168: 5629-5637
220. Joyee AG, Yang X. Role of toll-like receptors in immune responses to chlamydial infections. Curr Pharm Des 2008; 14(6): 593-600.
221. Wong JP, Christopher ME, Viswanathan S, Dai X, Salazar AM, Sun LQ, et al. Antiviral role of toll-like receptor-3 agonists against seasonal and avian influenza viruses. Curr Pharm Des 2009; 15(11): 1269-1274
222. Zwanziger D, Beck-Sickinger AG. Radiometal targeted tumor diagnosis and therapy with peptide hormones. Curr Pharm Des 2008; 14(24): 2385-2400